EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 10

California poppy Eschscholzia californica Cham.

Also called: Eschscholziae herba, Goldmohnkraut (German), Chryseis californica (synonym)

California poppy is a flowering plant of the poppy family. Its dried above-ground parts are used in European traditional herbal medicines for mild stress and sleep; its main alkaloids include californidine, escholtzine and protopine. Clinical evidence is limited.

Category
Botanical
Part used
Above-ground parts (herb), dried and powdered
Strongest evidence
C Limited
Native range
Native to the western and south-central United States and northern Mexico (POWO: "W. & S. Central U.S.A. to N. Mexico")
Reviewed
2026-10-29

Class 3 Limited studies in people. The EMA assessment report (2015) lists no randomized trial of California poppy alone: one open study (60 patients with sleep disorders) and one open-label trial (20 patients with chronic pain); its only RCT tested a combination with hawthorn and magnesium. [10]

Fact-checked 2026-10-29 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied1 body area · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what California poppy does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for California poppy, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Mild-to-moderate generalized anxiety (combination product)CA 3-month RCT in 264 adults tested tablets combining California poppy, hawthorn and magnesium: Hamilton anxiety scores fell 10.6 vs 8.9 points with placebo. The poppy's own contribution cannot be separated. [3]
Sleep (EU traditional use)CThe EMA herbal committee found clinical trial evidence insufficient but accepted traditional use to aid sleep; it considered a few studies, including one in sleep disorders suggesting a positive effect. [4]
Insomnia (multi-ingredient product)CAn open-label pilot in 40 adults (2 weeks of a product with melatonin, vitamin B6, California poppy, passionflower and lemon balm) reported better sleep-diary scores; there was no control group. [6]

Main constituents: Alkaloids californidine, escholtzine and protopine (main alkaloids) [1]; Allocryptopine is also among the major alkaloids isolated [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • EU traditional-use monograph (EMA/HMPC, adopted 28 January 2015), adults: powdered herbal substance 480-600 mg per single dose, 960-1,500 mg per day; for sleep, one dose with dinner and one 30-60 minutes before bedtime. [5]
  • Combination tablets (hawthorn, California poppy, magnesium): two tablets twice daily for 3 months (anxiety RCT). [3]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use is not recommended.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    1 listed

    CYP3A4, CYP2C9, CYP2C19 and CYP2D6 substrates (laboratory data)

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU (EMA/HMPC monograph, adopted 28 January 2015), traditional use, adults and elderly: powdered herbal substance, single dose 480-600 mg, daily dose …

    Details and sources
  • EU monograph: may impair the ability to drive and use machines; affected people should not drive or operate machinery. [5]
  • EU monograph: use under 18 years is not recommended, and use in pregnancy and breastfeeding is not recommended because safety has not been established. [5]
  • At the time of the HMPC assessment, no side effects had been reported with California poppy medicines. [4]
  • In the 3-month combination trial, 11.5% of the active group and 9.7% of the placebo group reported adverse events, mainly mild or moderate digestive or psychopathological disorders. [3]
Interactions

Interactions

Known interactions of California poppy
WithWhat happens
Drugs metabolized by CYP3A4, CYP2C9, CYP2C19 or CYP2D6 (laboratory data)In laboratory tests, an ethanol extract inhibited these enzymes and activated PXR, as did some isolated alkaloids, while a tea (water extract) did not; the authors concluded ethanol extracts may cause drug interactions. The EU monograph lists none reported. [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • In eight commercial California poppy products, californidine ranged from 0.13 to 2.55 mg/g, escholtzine from 0.05 to 0.63 mg/g and protopine from 0.008 to 0.200 mg/g (UHPLC-MS/MS). [1]
Regulation

Regulatory status

  • EU: an EMA/HMPC monograph (2015) supports traditional herbal medicinal products for relief of mild symptoms of mental stress and to aid sleep, in adults, based on long-standing use. [5]
  • US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
  • US: No NDI notification naming California poppy (Eschscholzia californica) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [9]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Californidine, escholtzine and protopine (main alkaloids) Alkaloids [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming California poppy (Eschscholzia californica) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of California poppy (Eschscholzia californica) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
  • NTP technical reports list checked 2026-10-29: no report on California poppy found. [P4]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • CYP3A4, CYP2C9, CYP2C19 and CYP2D6 substrates (laboratory data): In vitro, the ethanol extract inhibited these enzymes and activated PXR; escholtzine and allocryptopine inhibited CYP3A4, 2C9 and 2C19, and protopine and allocryptopine inhibited CYP2D6. The tea and californidine had no effect. [P5]
  • Other medicines: EU monograph section 4.5 (interactions): none reported. [P6]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P7]
  • Quantification of californidine, escholtzine and protopine (e.g., UHPLC-MS/MS) — Alkaloid content differed severalfold among eight commercial products (Chauveau et al. 2023). [P1]

Supply and conservation

  • EMA: the plant is cultivated or gathered when flowering to obtain the above-ground parts for medicinal use. [P8]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU (EMA/HMPC monograph, adopted 28 January 2015), traditional use, adults and elderly: powdered herbal substance, single dose 480-600 mg, daily dose 960-1,500 mg; for sleep, one dose with dinner and one 30-60 min before bedtime. Not recommended under 18. [P6]

Pregnancy and breastfeeding

  • EU monograph: safety during pregnancy and lactation has not been established; in the absence of sufficient data, use is not recommended. No fertility data available. [P6]

Sources for this profile

  1. Chauveau A, et al. Alkaloids in commercial preparations of California poppy - quantification, intestinal permeability and microbiota interactions. Biomed Pharmacother 2023;166:115420 (PMID 37673017), 2023-10. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
  4. National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  5. Manda VK, et al. Modulation of CYPs, P-gp, and PXR by Eschscholzia californica (California poppy) and its alkaloids. Planta Med 2016;82(6):551-8 (PMID 27054913), 2016-04. pubmed.ncbi.nlm.nih.gov
  6. European Medicines Agency, HMPC. European Union herbal monograph on Eschscholzia californica Cham., herba, EMA/HMPC/680372/2013 (final, adopted 28 January 2015), 2015-01-28. ema.europa.eu
  7. eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
  8. European Medicines Agency. Eschscholziae herba (California poppy): herbal summary for the public, EMA/HMPC/334023/2015 (first published 03/08/2015), 2015-08-03. ema.europa.eu
Sources

Sources

  1. Chauveau A, et al. Alkaloids in commercial preparations of California poppy - quantification, intestinal permeability and microbiota interactions. Biomed Pharmacother 2023;166:115420 (PMID 37673017), 2023-10. pubmed.ncbi.nlm.nih.gov
  2. Manda VK, et al. Modulation of CYPs, P-gp, and PXR by Eschscholzia californica (California poppy) and its alkaloids. Planta Med 2016;82(6):551-8 (PMID 27054913), 2016-04. pubmed.ncbi.nlm.nih.gov
  3. Hanus M, et al. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin 2004;20(1):63-71 (PMID 14741074), 2004-01. pubmed.ncbi.nlm.nih.gov
  4. European Medicines Agency. Eschscholziae herba (California poppy): herbal summary for the public, EMA/HMPC/334023/2015 (first published 03/08/2015), 2015-08-03. ema.europa.eu
  5. European Medicines Agency, HMPC. European Union herbal monograph on Eschscholzia californica Cham., herba, EMA/HMPC/680372/2013 (final, adopted 28 January 2015), 2015-01-28. ema.europa.eu
  6. Lemoine P, et al. A combination of melatonin, vitamin B6 and medicinal plants in the treatment of mild-to-moderate insomnia: a prospective pilot study. Complement Ther Med 2019;45:104-108 (PMID 31331545), 2019-08. pubmed.ncbi.nlm.nih.gov
  7. Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Eschscholzia californica Cham. (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
  8. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  9. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  10. European Medicines Agency, HMPC. Assessment report on Eschscholzia californica Cham., herba, EMA/HMPC/680375/2013 (final, 28 January 2015), 2015-01-28. ema.europa.eu
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.